Literature DB >> 15723718

Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects.

Yoshimitsu Niwa1, Kaoru Hirose, Keitaro Matsuo, Kazuo Tajima, Yoko Ikoma, Toru Nakanishi, Akihiro Nawa, Kazuo Kuzuya, Akiko Tamakoshi, Nobuyuki Hamajima.   

Abstract

To test the association of endometrial cancer with the p73 G4C14-to-A4T14 polymorphism in exon 2 and the p53 Arg72Pro polymorphism, an incident case-control study was performed in Japanese subjects. The cases comprised 114 endometrial cancer patients, and the controls were 320 healthy females and 122 noncancer female outpatients. An unconditional logistic regression model demonstrated a significant association between the p73 AA genotype and an increased risk of endometrial cancer (OR=2.82, 95% CI=1.36-5.82), especially of type-I tumors (OR=3.24, 95% CI=1.53-6.87). In contrast, there was no significant difference in the p53 Arg72Pro genotype frequency between the controls and cases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723718     DOI: 10.1016/j.canlet.2004.10.018

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

Review 1.  Single-nucleotide polymorphisms in the p53 signaling pathway.

Authors:  Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

2.  TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis.

Authors:  De-Ke Jiang; Lei Yao; Wei-Hua Ren; Wen-Zhang Wang; Bo Peng; Long Yu
Journal:  Med Oncol       Date:  2010-06-15       Impact factor: 3.064

3.  Role of p53 and p73 genes polymorphisms in susceptibility to esophageal cancer: a case control study in a northern Indian population.

Authors:  Meenakshi Umar; Rohit Upadhyay; Rohini Khurana; Shaleen Kumar; Uday Chand Ghoshal; Balraj Mittal
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

4.  Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk.

Authors:  Lan Wang; Rui Gao; Long Yu
Journal:  Mol Biol Rep       Date:  2011-05-27       Impact factor: 2.316

5.  Association of p73 gene G4C14-A4T14 polymorphism and MDM2 gene SNP309 with non-small cell lung cancer risk in a Chinese population.

Authors:  Wen Li; Shuang Shuang Wang; Jing Deng; Jian Xin Tang
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

Review 6.  Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis.

Authors:  Mohammad Haroon Khan; Aftab Khalil; Hamid Rashid
Journal:  Genet Res (Camb)       Date:  2015-04-17       Impact factor: 1.588

7.  An eleven autophagy-related genes-based prognostic signature for endometrial carcinoma.

Authors:  Shiyang Li; Junan Pan; Yanyu Zhang; Yan Tang; Xiaobing Zeng; Shihai Wang; Dengxuan Wu; Yuyong Liu; Dawen Xu; Jianjun Lan; Dong Hu
Journal:  J Egypt Natl Canc Inst       Date:  2022-10-10

8.  Susceptibility to Helicobacter pylori infection: results of an epidemiological investigation among gastric cancer patients.

Authors:  Nikola Panic; Elena Mastrostefano; Emanuele Leoncini; Roberto Persiani; Dario Arzani; Rosarita Amore; Riccardo Ricci; Federico Sicoli; Stefano Sioletic; Milutin Bulajic; Domenico D' Ugo; Walter Ricciardi; Stefania Boccia
Journal:  Mol Biol Rep       Date:  2014-02-14       Impact factor: 2.316

9.  Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population.

Authors:  Benyuan Deng; Fei Liu; Yonggang Wei; Limei Luo; Xi Chen; Lvnan Yan; Bo Li
Journal:  Tumour Biol       Date:  2012-10-12

10.  Major regulators of microRNAs biogenesis Dicer and Drosha are down-regulated in endometrial cancer.

Authors:  Anna Torres; Kamil Torres; Tomasz Paszkowski; Barbara Jodłowska-Jędrych; Tomasz Radomański; Andrzej Książek; Ryszard Maciejewski
Journal:  Tumour Biol       Date:  2011-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.